ImmuneCare Biopharmaceuticals

ImmuneCare Biopharmaceuticals (also known as ImmuQuad) is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in immune repertoire sequencing and the development of precision immunotherapies. The company utilizes its proprietary high-throughput sequencing platform, ImmuQuad, to analyze T-cell and B-cell receptors with high sensitivity and specificity. Its lead commercial product, Seq-MRD, provides advanced Minimal Residual Disease monitoring for patients with hematological malignancies such as leukemia and lymphoma. Beyond diagnostics, ImmuneCare leverages its extensive immune database to discover and develop novel TCR-T and CAR-T cell therapies targeting solid tumors and blood cancers. The company aims to integrate immune big data with clinical applications to provide personalized treatment solutions for cancer and autoimmune diseases.